135 related articles for article (PubMed ID: 36510033)
1. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug-drug interactions.
Li Z; Zhang Q; He H; Sun N; Zhang R; Yang CQ; Zhao LB
Cancer Chemother Pharmacol; 2023 Feb; 91(2):121-132. PubMed ID: 36510033
[TBL] [Abstract][Full Text] [Related]
2. Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.
Li Z; Sun N; Zhang Q; Ma HH; Wang D; Zhao YZ; Yang CQ; Zhang R; Zhao LB
Anal Methods; 2022 Jun; 14(23):2293-2303. PubMed ID: 35635540
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients.
Wang DD; Ye QF; Chen X; Xu H; Li ZP
Xenobiotica; 2020 Apr; 50(4):435-441. PubMed ID: 31382792
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.
Ge J; Zhang Q; Ma H; Wang D; Zhao Y; Zhu T; Wang W; Zhou C; Wei A; Lian H; Qin M; Yang J; Li Z; Wang T; Zhang R
Haematologica; 2024 Feb; 109(2):458-465. PubMed ID: 37470145
[TBL] [Abstract][Full Text] [Related]
5. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
[TBL] [Abstract][Full Text] [Related]
9. The Dosage Recommendation of Cyclosporin in Children with Hemophagocytic Lymphohistiocytosis based on Population Pharmacokinetic Model.
Yang Y; Li YF; Hu K; Zhang SJ; Cui JF; Huang XT; He SM; Wang DD; Chen X
Curr Pharm Des; 2023; 29(37):2996-3004. PubMed ID: 38062660
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Yan WL; Yang SL; Zhao FY; Xu XJ
J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
Trantham T; Auten J; Muluneh B; Van Deventer H
J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
[TBL] [Abstract][Full Text] [Related]
13. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
Zheng Y; Liu SP; Xu BP; Shi ZR; Wang K; Yang JB; Huang X; Tang BH; Chen XK; Shi HY; Zhou Y; Wu YE; Qi H; Jacqz-Aigrain E; Shen AD; Zhao W
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941652
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
Huang Z; Xie J
Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
[TBL] [Abstract][Full Text] [Related]
16. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
17. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
[No Abstract] [Full Text] [Related]
18. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
